Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Bought by Barclays PLC

Barclays PLC boosted its holdings in shares of Sutro Biopharma, Inc. (NASDAQ:STRO) by 385.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 273,019 shares of the company’s stock after buying an additional 216,757 shares during the period. Barclays PLC owned approximately 0.33% of Sutro Biopharma worth $944,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in STRO. XTX Topco Ltd grew its stake in Sutro Biopharma by 222.0% during the 3rd quarter. XTX Topco Ltd now owns 104,200 shares of the company’s stock valued at $361,000 after purchasing an additional 71,844 shares during the last quarter. Jane Street Group LLC increased its holdings in shares of Sutro Biopharma by 30.7% in the third quarter. Jane Street Group LLC now owns 108,192 shares of the company’s stock valued at $374,000 after purchasing an additional 25,416 shares during the period. State Street Corp increased its holdings in shares of Sutro Biopharma by 5.2% in the third quarter. State Street Corp now owns 1,647,162 shares of the company’s stock valued at $5,699,000 after purchasing an additional 81,855 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Sutro Biopharma by 1,195.1% in the third quarter. BNP Paribas Financial Markets now owns 82,524 shares of the company’s stock valued at $286,000 after purchasing an additional 76,152 shares during the period. Finally, FMR LLC increased its holdings in shares of Sutro Biopharma by 24.9% in the third quarter. FMR LLC now owns 189,041 shares of the company’s stock valued at $654,000 after purchasing an additional 37,701 shares during the period. 96.99% of the stock is owned by institutional investors and hedge funds.

Sutro Biopharma Trading Down 2.1 %

Shares of STRO opened at $1.85 on Tuesday. Sutro Biopharma, Inc. has a 12 month low of $1.70 and a 12 month high of $6.13. The stock’s 50 day moving average is $2.91 and its two-hundred day moving average is $3.47. The firm has a market cap of $152.55 million, a P/E ratio of -1.15 and a beta of 1.09.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on STRO shares. JMP Securities reissued a “market outperform” rating and issued a $17.00 price objective on shares of Sutro Biopharma in a report on Wednesday, December 11th. Wedbush reissued an “outperform” rating and issued a $8.00 price objective on shares of Sutro Biopharma in a report on Tuesday, December 10th. Piper Sandler reissued an “overweight” rating and issued a $11.00 price objective on shares of Sutro Biopharma in a report on Friday, October 11th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Sutro Biopharma in a report on Monday, November 18th. Finally, Wells Fargo & Company dropped their target price on Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating on the stock in a report on Wednesday, December 11th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $11.13.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.